Non-small Cell Lung Cancer Clinical Trials in Changsha, Hunan
17 recruitingChangsha, Hunan, China
Showing 1–17 of 17 trials
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled212 locationsNCT06345729
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled204 locationsNCT06422143
Recruiting
Phase 3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Non-small Cell Lung Cancer
Bristol-Myers Squibb1,000 enrolled280 locationsNCT06561386
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled67 locationsNCT05579366
Recruiting
Phase 1
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
MelanomaNon-small Cell Lung CancerRenal Cell Carcinoma
Shanghai Henlius Biotech174 enrolled69 locationsNCT07160335
Recruiting
Phase 2
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Non-small Cell Lung CancerNasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.121 enrolled16 locationsNCT05956587
Recruiting
Phase 2
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Teligene US99 enrolled26 locationsNCT05168566
Recruiting
Phase 1Phase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Non-small Cell Lung CancerKRAS P.G12C
Allist Pharmaceuticals, Inc.240 enrolled27 locationsNCT05288205
Recruiting
Phase 1Phase 2
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc.104 enrolled21 locationsNCT05276726
Recruiting
Phase 3
Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital210 enrolled1 locationNCT05549037
Recruiting
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital800 enrolled1 locationNCT04324164
Recruiting
Phase 3
Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.
Non-small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.518 enrolled71 locationsNCT05922345
Recruiting
Phase 2
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital90 enrolled1 locationNCT05014464
Recruiting
Phase 2
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital100 enrolled1 locationNCT06355609
Recruiting
Phase 2
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital120 enrolled1 locationNCT04322578
Recruiting
Phase 2Phase 3
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital1,200 enrolled1 locationNCT04322617
Recruiting
Phase 1Phase 2
H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC
Non-small Cell Lung Cancer
RedCloud Bio76 enrolled8 locationsNCT05552781